|
Title
|
|
|
|
The role of positron emission tomography with -fluoro-2-deoxy-D-glucose in respiratory oncology
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| In the past 5 yrs, positron emission tomography (PET) with 18F-fluoro-2-deoxy-d-glucose (FDG) has become an important imaging modality in lung cancer patients. At this time, the indication of FDG-PET as a complimentary tool to computed tomography in the diagnosis and staging of non-small cell lung cancer has gradually gained more widespread acceptance and also reimbursement in many European countries. This review focuses on the data of FDG-PET in the diagnosis of lung nodules and masses, and in locoregional and extrathoracic staging of non-small cell lung cancer. Emphasis is put on the potential clinical implementation of the currently available FDG-PET data. The use of FDG-PET in these indications now needs further validation in large-scale multicentre randomized studies, focusing mainly on treatment outcome parameters, survival and cost-efficacy. Interesting findings with 18F-fluoro-2-deoxy-d-glucose-positron emission tomography have also been reported for the evaluation of response to radio- or chemotherapy, in radiotherapy planning, recurrence detection and assessment of prognosis. Finally, a whole new field of application of positron emission tomography in molecular biology, using new radiopharmaceuticals, is under extensive investigation. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
The European respiratory journal / European Respiratory Society [Lausanne] - Copenhagen, 1988, currens
|
|
|
Publication
|
|
|
|
Copenhagen
:
2001
|
|
|
ISSN
|
|
|
|
0903-1936
[print]
1399-3003
[online]
|
|
|
DOI
|
|
|
|
10.1183/09031936.01.17408020
|
|
|
Volume/pages
|
|
|
|
17
:4
(2001)
, p. 802-820
|
|
|
ISI
|
|
|
|
000169050400032
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|